Journal Menu

The Promising Frontier of Nanomedicine: Precision Diagnostics and Therapeutics

Swarup K Chakrabarti1 and Dhrubajyoti Chattopadhyay 1,2

1H. P. Ghosh Research Center, New Town, West Bengal 700161, India.
2Sister Nivedita University, New Town, West Bengal 700156, India.

*Corresponding author

*Swarup K. Chakrabarti. H. P. Ghosh Research Center, New Town, Kolkata, West Bengal 700161, India.Email: swarupkchakrabarti@gmail.com. Phone: (91) 9831643038.

Abstract

Nanomedicine is transforming healthcare by integrating nanotechnology with medical science to enhance diagnostics, treatment, and disease management. Leveraging the unique properties of nanoscale materials, nanomedicine provides innovative solutions that surpass traditional methods in precision and effectiveness. Advances such as quantum dots and gold nanoparticles have revolutionized diagnostic imaging, offering unprecedented sensitivity and clarity. Lab-on-a-Chip (LOC) systems, enhanced with nanoparticles, enable high-throughput and rapid pathogen detection, improving diagnostic accuracy. In therapy, nanomedicine excels in targeted drug delivery, particularly in oncology, where nanoparticles direct treatments to tumor sites, reducing side effects and enhancing efficacy. Nano vaccines further demonstrate this potential, providing controlled antigen release and versatility in administration, promising improvements across infectious diseases, cancers, and autoimmune disorders.

Nanomedicine also advances cardiovascular and neurological disease management through improved imaging and targeted therapies. Future developments are expected to focus on smart nanomaterials, artificial intelligence (AI) integration, and addressing environmental and public health challenges. Strategic investment and interdisciplinary collaboration will be crucial for advancing these innovations, ultimately transforming personalized medical care and addressing complex medical challenges with enhanced precision.

Key words: Nanomedicine, Tumor sites, Oncology, Infectious diseases, Cancers, and Autoimmune disorders

Introduction

Nanomedicine, situated at the confluence of nanotechnology and healthcare, is poised to transform public health through its advanced capabilities in diagnostics and treatment. By harnessing the unique properties of nanoscale materials, nanomedicine offers innovative solutions that significantly surpass conventional methods [1-5]. In the realm of diagnostic imaging, nanotechnology has introduced revolutionary changes. Quantum dots enable multicolor imaging with up to 100 times greater sensitivity compared to traditional dyes. Gold nanoparticles (NPs) enhance computed tomography (CT) scans by improving tumor delineation, while magnetic NPs refine magnetic resonance imaging (MRI), providing clearer images of tumor boundaries [6-10].

Lab-on-a-Chip (LOC) systems represent another significant advancement in diagnostic technology. These systems integrate multiple analyses onto a single chip, including biochemical operations and DNA sequencing. The use of NPs within LOC systems enhances high-throughput screening and analysis, such as isolating and analyzing circulating tumor cells (CTCs) and enabling rapid pathogen detection, thereby delivering timely and accurate diagnoses in point-of-care settings [11-13]. A major breakthrough in this field is the ability to target diseases with unparalleled specificity. Engineered NPs can precisely deliver therapeutic agents to malignant tissues, such as cancer cells, while sparing healthy ones [14, 15]. This targeted approach minimizes collateral damage and enhances treatment efficacy, leading to markedly improved outcomes in cancer therapy. The development of advanced NP delivery systems is pivotal in reducing side effects and enhancing the effectiveness of treatments [16].

Nanomedicine also brings substantial benefits to stem cell therapy [17-20]. NPs play a critical role in protecting stem cells from degradation, improving their survival rates, and aiding their integration into target tissues. Additionally, they enable real-time tracking of stem cell treatments, offering valuable insights and facilitating more precise interventions in regenerative medicine. Innovations in drug delivery and theranostics further highlight nanomedicine’s potential. Theranostics, which combines therapeutic and diagnostic functions within NPs, allows for the simultaneous delivery of drugs and imaging agents [21, 22]. This dual functionality supports real-time monitoring of therapeutic responses, exemplified by recent advancements such as FDA-approved radionuclide therapies, including lutetium-177 (177Lu) DOTATATE and 177Lu-prostate-specific membrane antigen (PSMA) therapies [23, 24]. Hence, this mini review will explore these cutting-edge advancements in nanomedicine, illustrating how they are reshaping diagnostics and therapeutic strategies in contemporary healthcare.

Nanomedicine: Revolutionizing Healthcare Across Diverse Domains

Nanomedicine is transforming healthcare by leveraging the unique properties of nanoscale materials to enhance various medical fields [1-5]. Its impact is profound, influencing diagnostics, treatment, and disease management with unprecedented precision and effectiveness. NPs, due to their size and surface characteristics, can interact with biological systems at a molecular level, allowing for highly targeted approaches. In diagnostics, nanomedicine enables earlier and more accurate disease detection through advanced imaging and biomarker identification [25, 26]. Therapeutically, it facilitates targeted drug delivery, minimizing side effects and maximizing therapeutic efficacy. Moreover, in disease management, nanomedicine offers innovative solutions for monitoring disease progression and optimizing treatment strategies [1-5, 27, 28].

As we delve deeper into these advancements, it becomes clear that nanomedicine holds the ultimate promise for revolutionizing healthcare by addressing complex medical challenges with precision and tailored solutions. The following subsections will explore the application of nanomedicine for diagnosing and treating selected diseases.

Cancer Diagnosis and Treatment

Nanomedicine has significantly advanced cancer care by improving drug delivery and diagnostic techniques [29, 30]. Liposomal NPs, such as Doxil, encapsulate chemotherapy drugs like Doxorubicin, targeting tumor sites and reducing systemic toxicity [31, 32]. Gold NPs (GNPs) are used in photothermal therapy to generate localized heat upon exposure to near-infrared (NIR) light, effectively abating cancer cells while protecting healthy tissue [33, 34]. Nanocarriers that combine chemotherapy drugs with imaging agents facilitate targeted drug delivery and non-invasive monitoring of treatment responses through imaging modalities like MRI [35, 36].

RNA interference (RNAi) NPs are emerging as a powerful tool in precision oncology, delivering small interfering RNA (siRNA) or microRNA (miRNA) to silence oncogenes or enhance tumor suppressor genes [37, 38]. NP-based immunotherapy is gaining attention for its potential to modulate immune responses against cancer cells, particularly in immunologically "cold" tumors by reactivating dormant immune cells [39, 40]. Clinical trials, such as those for BIND-014 and MM-398, have shown promising results, underscoring the potential for improved efficacy and reduced side effects [41, 42].

Infectious Disease Diagnosis and Treatment

Nanomedicine enhances infectious disease management through advanced NP-based methods. GNPs in lateral flow assays enable rapid pathogen identification, including HIV (Human Immunodeficiency Virus), influenza, and COVID-19 [43, 44]. In treatment, liposomal amphotericin B (AmBisome) improves the pharmacokinetics and reduces toxicity of antifungal drugs, while silver NPs (AgNPs) show promise against multidrug-resistant (MDR) bacterial infections [45-47]. Polymer-based nanosystems, such as dendrimers, enhance antiviral agent delivery for diseases like HIV/AIDS (acquired immunodeficiency syndrome), providing prolonged drug release and improved bioavailability [48-50].

Cardiovascular Disease Diagnosis and Management

Nanomedicine is revolutionizing the diagnosis and management of cardiovascular diseases (CVDs) through a range of innovative approaches. In diagnostics, magnetic NPs enhance MRI imaging, delivering clearer and more detailed views of heart tissues and blood vessels [51, 52]. Gold NPs improve CT scans by offering better delineation of tumors and arterial plaques [53], while quantum dots enable highly sensitive detection of cardiovascular biomarkers such as troponin and BNP (B-type natriuretic peptide), facilitating earlier diagnosis [54, 55]. LOC systems further streamline diagnostics by analyzing multiple biomarkers from a single sample, which allows for rapid and precise assessments. For instance, NP-based biosensors can detect elevated levels of cardiac biomarkers like C-reactive protein (CRP) in blood, providing real-time insights into inflammation and cardiovascular risk [56-58].

In terms of management, nanomedicine offers advanced solutions for treating cardiovascular conditions. Polymeric NPs enhance the delivery of antihypertensive medications, improving blood pressure control with fewer side effects [59, 60]. Targeted NPs are employed to deliver anti-inflammatory drugs directly to atherosclerotic plaques, reducing both inflammation and plaque size [61, 62]. Magnetic NPs combined with thrombolytic agents allow for targeted clot dissolution, while liposomal NPs deliver anti-inflammatory drugs to inflamed cardiac tissues [63, 64]. In stroke therapy, GNPs improve the delivery of neuroprotective agents to ischemic brain regions, and biodegradable NPs assist in cardiac tissue regeneration after myocardial infarction [65, 66]. Additionally, inhalable NPs can carry vasodilatory drugs for treating pulmonary arterial hypertension [67]. These advancements collectively contribute to more accurate diagnostics and enhanced management of CVDs.

Neurological Disease Diagnosis and Treatment

Nanomedicine significantly advances the diagnosis and treatment of neurological diseases through enhanced imaging techniques and targeted drug delivery. In diagnostics, magnetic NPs improve MRI by providing clearer images of brain structures and lesions, aiding in precise localization of abnormalities [8, 68]. Quantum dots facilitate high-resolution imaging of cellular and molecular targets, allowing for detailed visualization of disease-specific changes [6, 10]. For example, NPs targeting amyloid-β plaques can detect early signs of Alzheimer's disease (AD), while gadolinium-based NPs enhance the imaging of multiple sclerosis (MS) lesions [69, 70]. LOC systems enable the rapid, simultaneous analysis of biomarkers such as neurofilament light chain (NfL) levels, leading to early and accurate diagnoses [71, 72].

In the realm of treatment, nanomedicine addresses the challenge of crossing the blood-brain barrier (BBB), a significant obstacle in treating neurological disorders. Engineered NPs use receptor-mediated and adsorptive-mediated transcytosis to traverse the BBB, protecting drugs from degradation and ensuring their sustained release [73, 74]. This targeted delivery to specific brain regions enhances therapeutic efficacy while reducing systemic toxicity. Case studies further illustrate nanomedicine’s impact on neurological diseases. For AD, curcumin-loaded NPs target amyloid-β plaques, potentially slowing progression [75, 76]. In glioblastoma multiforme, polymeric NPs improve chemotherapy delivery to tumor sites, overcoming resistance and minimizing toxicity [77, 78]. Post-stroke therapies utilize NPs to deliver neuroprotective agents and growth factors, aiming to reduce inflammation and support recovery [79, 80]. In MS, NPs transport immunomodulatory drugs to inflamed CNS areas, and in Parkinson's Disease (PD), they enhance dopamine replacement therapies [81-84].

Additionally, NP-based systems offer targeted relief for neuropathic pain with reduced side effects [85, 86]. These advancements underscore nanomedicine’s transformative potential in diagnosing and treating neurological conditions, offering personalized solutions, and improving patient outcomes.

Emerging Frontiers: Nanovaccine Innovations in Disease Treatment

Nanovaccines (NVs) represent a significant leap in immunization and disease treatment by leveraging nanotechnology to enhance vaccine efficacy, delivery, and safety. By encapsulating or adsorbing antigens and adjuvants, these advanced vaccines ensure superior antigen delivery to immune cells, eliciting more robust and targeted immune responses [87, 88]. Engineered NPs offer controlled release, maintaining prolonged antigen presence and immune stimulation. This feature not only improves vaccine stability and shelf life—particularly important in resource-limited settings—but also supports various administration routes such as intranasal, intravenous, transdermal, and oral. Furthermore, NVs can be designed to cross the BBB, enhancing their versatility and effectiveness [89, 90].

The flexibility of NVs extends to mucosal routes, including intranasal, oral, and sublingual administration [91, 92]. These methods can potentially increase patient compliance compared to traditional injections. By facilitating antigen uptake in mucosal-associated lymphoid tissues (MALT), NVs induce both local mucosal and systemic immunity, crucial for defending against pathogens entering through mucosal surfaces [93, 94]. NVs offer significant benefits over traditional vaccines through their ability to deliver precise doses and enhance immune responses. This technology is versatile and can be applied to a wide range of conditions, such as infectious diseases, cancers, and autoimmune disorders [95, 96].

NVs have shown promise against viral, bacterial, and parasitic infections with preclinical and clinical studies demonstrating efficacy against pathogens such as influenza, HIV, and malaria [96]. In cancer immunotherapy, they deliver tumor antigens and immunomodulators, potentially improving treatment outcomes [97]. Research is also exploring NVs for regulating immune responses in autoimmune diseases like MS and rheumatoid arthritis (RA), as well as for desensitizing the immune system in allergy treatments [98, 99]. Mucosal NVs, in particular, have demonstrated potential in preclinical studies by boosting immunoglobulin A (IgA) production and strengthening mucosal barriers. They also hold promise for stimulating immune responses against mucosal tumors and managing autoimmune disorders [91-94,100].

CONCLUSIONS, FUTURE DIRECTIONS, AND OPPORTUNITIES

Conclusions

Nanomedicine is at the forefront of a transformative shift in healthcare, delivering groundbreaking advancements in diagnostics, treatment, and disease management. By leveraging the unique properties of nanoscale materials, nanomedicine enhances the precision and efficacy of medical interventions across diverse domains, including cancer, infectious diseases, cardiovascular conditions, and neurological disorders. Key innovations such as targeted drug delivery systems, enhanced imaging techniques, and the development of NVs highlight the field’s potential to revolutionize patient care. These advancements promise to address complex medical challenges with unprecedented accuracy and pave the way for more personalized and effective treatment strategies. As research progresses, scientists will drive significant breakthroughs in nanomedicine, shaping the future of healthcare with enhanced precision and tailored solutions.

Future Directions

Looking ahead, several promising advancements are poised to shape the future of  nanomedicine. The development of smart nanomaterials is expected to play a pivotal role in achieving highly precise drug delivery. Integrating AI will enhance nanoparticle design and treatment strategies, optimizing therapeutic outcomes. Advancements in nanorobotics may enable targeted therapies and microsurgical procedures, addressing complex challenges such as treating neurological disorders and customizing implants and scaffolds using 3D printing [101]. Additionally, innovations in environmental applications of nanomedicine could improve pollution detection and remediation, contributing to a healthier ecosystem [102].

Opportunities in Public Health

Nanomedicine holds significant potential to drive transformative changes in public health. The evolution of sophisticated nanoscale diagnostic tools is anticipated to enable earlier and more accurate disease detection, facilitating prompt interventions and reducing economic burdens. NP-based vaccines and intelligent drug delivery systems will revolutionize immunization and treatment approaches, especially in response to global health crises.  Furthermore, integrating nanotechnology with AI-driven environmental monitoring could enhance the quality of air, water, and food, promoting healthier communities.

Strategic Research Priorities and Funding

Advancing nanomedicine will require strategic focus on key research priorities, including the development of nanoscale diagnostic technologies, targeted drug delivery systems, and nanomaterials for regenerative medicine. We should place emphasis on ensuring long-term safety, biocompatibility, and environmental impact. Securing funding from government grants, private sector investments, and collaborative efforts between academia, industry, and healthcare will be crucial in supporting these innovative projects.

Addressing Barriers

To overcome existing barriers in nanomedicine, a multifaceted approach is essential. Enhancing interdisciplinary collaboration, investing in comprehensive safety research, and streamlining regulatory processes will be critical. Educational initiatives and awareness campaigns can foster a broader understanding and adoption of nanomedicine technologies. Moreover, global partnerships and funding initiatives should aim to promote equitable access to these advancements, driving innovation and harnessing the transformative potential of nanomedicine.

By addressing these priorities and leveraging emerging opportunities, the field of nanomedicine is poised to make a profound impact on healthcare, offering innovative solutions and improved outcomes across various medical challenges.

Funding

The research is funded through an intramural grant from the Bandhan Group, including Bandhan Bank and its affiliated organizations.

REFERENCES

  1. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. Nat Rev Cancer. 2017 Jan;17(1):20-37. doi: 10.1038/nrc.2016.108.
  2. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MDP, Acosta-Torres LS, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018 Sep 19;16(1):71. doi: 10.1186/s12951-018-0392-8.
  3. Martín Giménez VM, Kassuha DE, Manucha W. Nanomedicine applied to cardiovascular diseases: latest developments. Ther Adv Cardiovasc Dis. 2017 Apr;11(4):133-142. doi: 10.1177/1753944717692293.
  4. Alghamdi MA, Fallica AN, Virzì N, Kesharwani P, Pittalà V, Greish K. The Promise of Nanotechnology in Personalized Medicine. J Pers Med. 2022 Apr 22;12(5):673. doi: 10.3390/jpm12050673.
  5. Mabrouk M, Das DB, Salem ZA, Beherei HH. Nanomaterials for Biomedical Applications: Production, Characterisations, Recent Trends and Difficulties. Molecules. 2021 Feb 18;26(4):1077. doi: 10.3390/molecules26041077.
  6. Le N, Kim K. Current Advances in the Biomedical Applications of Quantum Dots: Promises and Challenges. Int J Mol Sci. 2023 Aug 11;24(16):12682. doi: 10.3390/ijms241612682.
  7. Bouché M, Hsu JC, Dong YC, Kim J, Taing K, Cormode DP. Recent Advances in Molecular Imaging with Gold Nanoparticles. Bioconjug Chem. 2020 Feb 19;31(2):303-314. doi: 10.1021/acs.bioconjchem.9b00669.
  8. Sun C, Lee JSH, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliv Rev. 2008 Aug 17;60(11):1252-1265. doi: 10.1016/j.addr.2008.03.018.
  9. Kaittanis C, Shaffer TM, Thorek DL, Grimm J. Dawn of advanced molecular medicine: nanotechnological advancements in cancer imaging and therapy. Crit Rev Oncog. 2014;19(3-4):143-76. doi: 10.1615/critrevoncog.2014011601.
  10. Matea CT, Mocan T, Tabaran F, Pop T, Mosteanu O, et al. Quantum dots in imaging, drug delivery and sensor applications. Int J Nanomedicine. 2017 Jul 28;12:5421-5431. doi: 10.2147/IJN.S138624.
  11. García-Hernández LA, Martínez-Martínez E, Pazos-Solís D, Aguado-Preciado J, Dutt A, Chávez-Ramírez AU, et al. Optical Detection of Cancer Cells Using Lab-on-a-Chip. Biosensors (Basel). 2023 Mar 30;13(4):439. doi: 10.3390/bios13040439.
  12. Zhu H, Fohlerová Z, Pekárek J, Basova E, Neužil P. Recent advances in lab-on-a-chip technologies for viral diagnosis. Biosens Bioelectron. 2020 Apr 1;153:112041. doi: 10.1016/j.bios.2020.112041.
  13. Iqbal MJ, Javed Z, Herrera-Bravo J, Sadia H, Anum F, Raza S, et al. Biosensing chips for cancer diagnosis and treatment: a new wave towards clinical innovation. Cancer Cell Int. 2022 Nov 15;22(1):354. doi: 10.1186/s12935-022-02777-7.
  14. Baranwal J, Barse B, Di Petrillo A, Gatto G, Pilia L, Kumar A. Nanoparticles in Cancer Diagnosis and Treatment. Materials (Basel). 2023 Jul 30;16(15):5354. doi: 10.3390/ma16155354.
  15. Gavas S, Quazi S, Karpiński TM. Nanoparticles for Cancer Therapy: Current Progress and Challenges. Nanoscale Res Lett. 2021 Dec 5;16(1):173. doi: 10.1186/s11671-021-03628-6.
  16. Cheng X, Xie Q, Sun Y. Advances in nanomaterial-based targeted drug delivery systems. Front Bioeng Biotechnol. 2023 Apr 13;11:1177151. doi: 10.3389/fbioe.2023.1177151.
  17. Desai D, Shende P. Nanoconjugates-Based Stem Cell Therapy for the Management of COVID-19. Stem Cell Rev Rep. 2021 Feb;17(1):231-240. doi: 10.1007/s12015-020-10079-6.
  18. Vissers C, Ming GL, Song H. Nanoparticle technology and stem cell therapy team up against neurodegenerative disorders. Adv Drug Deliv Rev. 2019 Aug;148:239-251. doi: 10.1016/j.addr.2019.02.007.
  19. Wei M, Yang Z, Li S, Le W. Nanotherapeutic and Stem Cell Therapeutic Strategies in Neurodegenerative Diseases: A Promising Therapeutic Approach. Int J Nanomedicine. 2023 Feb 3;18:611-626. doi: 10.2147/IJN.S395010.
  20. Baydar SY, Ay HF, Cakir R. Frontiers of stem cell engineering for nanotechnology-mediated drug delivery systems. ADMET DMPK. 2024 Feb 14;12(2):225-237. doi: 10.5599/admet.2160.
  21. Hapuarachchige S, Artemov D. Theranostic Pretargeting Drug Delivery and Imaging Platforms in Cancer Precision Medicine. Front Oncol. 2020 Jul 22;10:1131. doi: 10.3389/fonc.2020.01131.
  22. Yasir M, Mishra R, Tripathi AS, Maurya RK, Shahi A, Zaki MEA, Al Hussain SA, Masand VH. Theranostics: a multifaceted approach utilizing nano-biomaterials. Discov Nano. 2024 Feb 26;19(1):35. doi: 10.1186/s11671-024-03979-w.
  23. Hennrich U, Eder M. [177Lu]Lu-PSMA-617 (PluvictoTM): The First FDA-Approved Radiotherapeutical for Treatment of Prostate Cancer. Pharmaceuticals (Basel). 2022 Oct 20;15(10):1292. doi: 10.3390/ph15101292.
  24. Shah HJ, Ruppell E, Bokhari R, Aland P, Lele VR, Ge C, McIntosh LJ. Current and upcoming radionuclide therapies in the direction of precision oncology: A narrative review. Eur J Radiol Open. 2023 Jan 31;10:100477. doi: 10.1016/j.ejro.2023.100477.
  25. Thwala LN, Ndlovu SC, Mpofu KT, Lugongolo MY, Mthunzi-Kufa P. Nanotechnology-Based Diagnostics for Diseases Prevalent in Developing Countries: Current Advances in Point-of-Care Tests. Nanomaterials (Basel). 2023 Mar 31;13(7):1247. doi: 10.3390/nano13071247.
  26. Malik S, Muhammad K, Waheed Y. Emerging Applications of Nanotechnology in Healthcare and Medicine. Molecules. 2023 Sep 14;28(18):6624. doi: 10.3390/molecules28186624.
  27. Yetisgin AA, Cetinel S, Zuvin M, Kosar A, Kutlu O. Therapeutic Nanoparticles and Their Targeted Delivery Applications. Molecules. 2020 May 8;25(9):2193. doi: 10.3390/molecules25092193.
  28. Liu Q, Zou J, Chen Z, He W, Wu W. Current research trends of nanomedicines. Acta Pharm Sin B. 2023 Nov;13(11):4391-4416. doi: 10.1016/j.apsb.2023.05.018.
  29. Xu M, Han X, Xiong H, Gao Y, Xu B, Zhu G, Li J. Cancer Nanomedicine: Emerging Strategies and Therapeutic Potentials. Molecules. 2023 Jun 30;28(13):5145. doi: 10.3390/molecules28135145.
  30. Chehelgerdi M, Chehelgerdi M, Allela OQB, Pecho RDC, Jayasankar N, Rao DP, et al. Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation. Mol Cancer. 2023 Oct 9;22(1):169. doi: 10.1186/s12943-023-01865-0.
  31. Fulton MD, Najahi-Missaoui W. Liposomes in Cancer Therapy: How Did We Start and Where Are We Now. Int J Mol Sci. 2023 Apr 1;24(7):6615. doi: 10.3390/ijms24076615.
  32. Lee J, Choi MK, Song IS. Recent Advances in Doxorubicin Formulation to Enhance Pharmacokinetics and Tumor Targeting. Pharmaceuticals (Basel). 2023 May 29;16(6):802. doi: 10.3390/ph16060802.
  33. Vines JB, Yoon JH, Ryu NE, Lim DJ, Park H. Gold Nanoparticles for Photothermal Cancer Therapy. Front Chem. 2019 Apr 5;7:167. doi: 10.3389/fchem.2019.00167.
  34. Doughty ACV, Hoover AR, Layton E, Murray CK, Howard EW, Chen WR. Nanomaterial Applications in Photothermal Therapy for Cancer. Materials (Basel). 2019 Mar 7;12(5):779. doi: 10.3390/ma12050779.
  35. Edis Z, Wang J, Waqas MK, Ijaz M, Ijaz M. Nanocarriers-Mediated Drug Delivery Systems for Anticancer Agents: An Overview and Perspectives. Int J Nanomedicine. 2021 Feb 17;16:1313-1330. doi: 10.2147/IJN.S289443. Erratum in: Int J Nanomedicine. 2021 Jul 27;16:5099. doi: 10.2147/IJN.S330286.
  36. Sun L, Liu H, Ye Y, Lei Y, Islam R, Tan S, Tong R, Miao YB, Cai L. Smart nanoparticles for cancer therapy. Signal Transduct Target Ther. 2023 Nov 3;8(1):418. doi: 10.1038/s41392-023-01642-x.
  37. Babu A, Muralidharan R, Amreddy N, Mehta M, Munshi A, Ramesh R. Nanoparticles for siRNA-Based Gene Silencing in Tumor Therapy. IEEE Trans Nanobioscience. 2016 Dec;15(8):849-863. doi: 10.1109/TNB.2016.2621730.
  38. Chen Z, Krishnamachary B, Pachecho-Torres J, Penet MF, Bhujwalla ZM. Theranostic small interfering RNA nanoparticles in cancer precision nanomedicine. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2020 Mar;12(2):e1595. doi: 10.1002/wnan.1595.
  39. Zhu X, Li S. Nanomaterials in tumor immunotherapy: new strategies and challenges. Mol Cancer. 2023 Jun 13;22(1):94. doi: 10.1186/s12943-023-01797-9.
  40. Suryavanshi P, Bodas D. Knockout cancer by nano-delivered immunotherapy using perfusion-aided scaffold-based tumor-on-a-chip. Nanotheranostics. 2024 Mar 31;8(3):380-400. doi: 10.7150/ntno.87818.
  41. Autio KA, Dreicer R, Anderson J, Garcia JA, Alva A, Hart LL, et al. Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer: A Phase 2 Clinical Trial. JAMA Oncol. 2018 Oct 1;4(10):1344-1351. doi: 10.1001/jamaoncol.2018.2168.
  42. Carnevale J, Ko AH. MM-398 (nanoliposomal irinotecan): emergence of a novel therapy for the treatment of advanced pancreatic cancer. Future Oncol. 2016 Feb;12(4):453-64. doi: 10.2217/fon.15.333.
  43. Ince B, Sezgintürk MK. Lateral flow assays for viruses diagnosis: Up-to-date technology and future prospects. Trends Analyt Chem. 2022 Dec;157:116725. doi: 10.1016/j.trac.2022.116725.
  44. Prakashan D, Shrikrishna NS, Byakodi M, Nagamani K, Gandhi S. Gold nanoparticle conjugate-based lateral flow immunoassay (LFIA) for rapid detection of RBD antigen of SARS-CoV-2 in clinical samples using a smartphone-based application. J Med Virol. 2023 Jan;95(1):e28416. doi: 10.1002/jmv.28416.
  45. Stone NR, Bicanic T, Salim R, Hope W. Liposomal Amphotericin B (AmBisome(®)): A Review of the Pharmacokinetics, Pharmacodynamics, Clinical Experience and Future Directions. Drugs. 2016 Mar;76(4):485-500. doi: 10.1007/s40265-016-0538-7.
  46. Moen MD, Lyseng-Williamson KA, Scott LJ. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs. 2009;69(3):361-92. doi: 10.2165/00003495-200969030-00010.
  47. Bruna T, Maldonado-Bravo F, Jara P, Caro N. Silver Nanoparticles and Their Antibacterial Applications. Int J Mol Sci. 2021 Jul 4;22(13):7202. doi: 10.3390/ijms22137202.
  48. Mamo T, Moseman EA, Kolishetti N, Salvador-Morales C, Shi J, Kuritzkes DR, et al. Emerging nanotechnology approaches for HIV/AIDS treatment and prevention. Nanomedicine (Lond). 2010 Feb;5(2):269-85. doi: 10.2217/nnm.10.1.
  49. Asl FD, Mousazadeh M, Taji S, Bahmani A, Khashayar P, Azimzadeh M, Mostafavi E. Nano drug-delivery systems for management of AIDS: liposomes, dendrimers, gold and silver nanoparticles. Nanomedicine (Lond). 2023 Feb;18(3):279-302. doi: 10.2217/nnm-2022-0248.
  50. Chakravarty M, Vora A. Nanotechnology-based antiviral therapeutics. Drug Deliv Transl Res. 2021 Jun;11(3):748-787. doi: 10.1007/s13346-020-00818-0.
  51. Caspani S, Magalhães R, Araújo JP, Sousa CT. Magnetic Nanomaterials as Contrast Agents for MRI. Materials (Basel). 2020 Jun 5;13(11):2586. doi: 10.3390/ma13112586.
  52. Lapusan R, Borlan R, Focsan M. Advancing MRI with magnetic nanoparticles: a comprehensive review of translational research and clinical trials. Nanoscale Adv. 2024 Apr 2;6(9):2234-2259. doi: 10.1039/d3na01064c.
  53. Cormode DP, Naha PC, Fayad ZA. Nanoparticle contrast agents for computed tomography: a focus on micelles. Contrast Media Mol Imaging. 2014 Jan-Feb;9(1):37-52. doi: 10.1002/cmmi.1551.
  54. Taghdiri A. Cardiovascular biomarkers: exploring troponin and BNP applications in conditions related to carbon monoxide exposure. Egypt Heart J. 2024 Jan 29;76(1):9. doi: 10.1186/s43044-024-00446-w.
  55. Shi C, Xie H, Ma Y, Yang Z, Zhang J. Nanoscale Technologies in Highly Sensitive Diagnosis of Cardiovascular Diseases. Front Bioeng Biotechnol. 2020 Jun 5;8:531. doi: 10.3389/fbioe.2020.00531.
  56. Abensur Vuillaume L, Frija-Masson J, Hadjiat M, Riquier T, d'Ortho MP, Le Borgne P, et al. Biosensors for the Rapid Detection of Cardiovascular Biomarkers of Vital Interest: Needs, Analysis and Perspectives. J Pers Med. 2022 Nov 22;12(12):1942. doi: 10.3390/jpm12121942.
  57. Gerdan Z, Saylan Y, Denizli A. Biosensing Platforms for Cardiac Biomarker Detection. ACS Omega. 2024 Feb 20;9(9):9946-9960. doi: 10.1021/acsomega.3c06571.
  58. Garg M, Sharma AL, Singh S. Advancement in biosensors for inflammatory biomarkers of SARS-CoV-2 during 2019-2020. Biosens Bioelectron. 2021 Jan 1;171:112703. doi: 10.1016/j.bios.2020.112703.
  59. Alam T, Khan S, Gaba B, Haider MF, Baboota S, Ali J. Nanocarriers as treatment modalities for hypertension. Drug Deliv. 2017 Nov;24(1):358-369. doi: 10.1080/10717544.2016.1255999.
  60. Story D, Aminoroaya A, Skelton Z, Kumari M, Zhang Y, Smith BR. Nanoparticle-Based Therapies in Hypertension. Hypertension. 2023 Dec;80(12):2506-2514. doi: 10.1161/HYPERTENSIONAHA.123.19523.
  61. Hossaini Nasr S, Huang X. Nanotechnology for Targeted Therapy of Atherosclerosis. Front Pharmacol. 2021 Nov 12;12:755569. doi: 10.3389/fphar.2021.755569.
  62. Pang AS, Dinesh T, Pang NY, Dinesh V, Pang KY, Yong CL, et al. Nanoparticles as Drug Delivery Systems for the Targeted Treatment of Atherosclerosis. Molecules. 2024 Jun 17;29(12):2873. doi: 10.3390/molecules29122873.
  63. Zhang B, Jiang X. Magnetic Nanoparticles Mediated Thrombolysis-A Review. IEEE Open J Nanotechnol. 2023;4:109-132. doi: 10.1109/ojnano.2023.3273921.
  64. MacRitchie N, Di Francesco V, Ferreira MFMM, Guzik TJ, Decuzzi P, Maffia P. Nanoparticle theranostics in cardiovascular inflammation. Semin Immunol. 2021 Aug;56:101536. doi: 10.1016/j.smim.2021.101536.
  65. Lv W, Liu Y, Li S, Lv L, Lu H, Xin H. Advances of nano drug delivery system for the theranostics of ischemic stroke. J Nanobiotechnology. 2022 May 31;20(1):248. doi: 10.1186/s12951-022-01450-5.
  66. Mohammadi Nasr S, Rabiee N, Hajebi S, Ahmadi S, Fatahi Y, Hosseini M, Bagherzadeh M, Ghadiri AM, Rabiee M, Jajarmi V, Webster TJ. Biodegradable Nanopolymers in Cardiac Tissue Engineering: From Concept Towards Nanomedicine. Int J Nanomedicine. 2020 Jun 18;15:4205-4224. doi: 10.2147/IJN.S245936.
  67. Kumbhare U, Yelne P, Tekale S. Therapeutic Use of an Inhaled Drug Delivery in Pulmonary Hypertension: A Review. Cureus. 2022 Oct 10;14(10):e30134. doi: 10.7759/cureus.30134.
  68. Farinha P, Coelho JMP, Reis CP, Gaspar MM. A Comprehensive Updated Review on Magnetic Nanoparticles in Diagnostics. Nanomaterials (Basel). 2021 Dec 17;11(12):3432. doi: 10.3390/nano11123432.
  69. Chakraborty A, Mohapatra SS, Barik S, Roy I, Gupta B, Biswas A. Impact of nanoparticles on amyloid β-induced Alzheimer's disease, tuberculosis, leprosy and cancer: a systematic review. Biosci Rep. 2023 Feb 27;43(2):BSR20220324. doi: 10.1042/BSR20220324.
  70. Saade C, Bou-Fakhredin R, Yousem DM, Asmar K, Naffaa L, El-Merhi F. Gadolinium and Multiple Sclerosis: Vessels, Barriers of the Brain, and Glymphatics. AJNR Am J Neuroradiol. 2018 Dec;39(12):2168-2176. doi: 10.3174/ajnr.A5773.
  71. Kouchaki E, Dashti F, Mirazimi SMA, Alirezaei Z, Jafari SH, Hamblin MR, Mirzaei H. Neurofilament light chain as a biomarker for diagnosis of multiple sclerosis. EXCLI J. 2021 Aug 16;20:1308-1325. doi: 10.17179/excli2021-3973.
  72. Teunissen CE, Kimble L, Bayoumy S, Bolsewig K, Burtscher F, Coppens S, et al. Methods to Discover and Validate Biofluid-Based Biomarkers in Neurodegenerative Dementias. Mol Cell Proteomics. 2023 Oct;22(10):100629. doi: 10.1016/j.mcpro.2023.100629.
  73. Hersh AM, Alomari S, Tyler BM. Crossing the Blood-Brain Barrier: Advances in Nanoparticle Technology for Drug Delivery in Neuro-Oncology. Int J Mol Sci. 2022 Apr 9;23(8):4153. doi: 10.3390/ijms23084153.
  74. Kulkarni M, Patel K, Patel A, Patel S, Desai J, Patel M, et al. Nanomaterials as drug delivery agents for overcoming the blood-brain barrier: A comprehensive review. ADMET DMPK. 2023 Oct 31;12(1):63-105. doi: 10.5599/admet.2043.
  75. Shabbir U, Rubab M, Tyagi A, Oh DH. Curcumin and Its Derivatives as Theranostic Agents in Alzheimer's Disease: The Implication of Nanotechnology. Int J Mol Sci. 2020 Dec 27;22(1):196. doi: 10.3390/ijms22010196.
  76. Salehi B, Calina D, Docea AO, Koirala N, Aryal S, Lombardo D, et al. Curcumin's Nanomedicine Formulations for Therapeutic Application in Neurological Diseases. J Clin Med. 2020 Feb 5;9(2):430. doi: 10.3390/jcm9020430.
  77. Caraway CA, Gaitsch H, Wicks EE, Kalluri A, Kunadi N, Tyler BM. Polymeric Nanoparticles in Brain Cancer Therapy: A Review of Current Approaches. Polymers (Basel). 2022 Jul 21;14(14):2963. doi: 10.3390/polym14142963.
  78. Rodà F, Caraffi R, Picciolini S, Tosi G, Vandelli MA, Ruozi B, et al. Recent Advances on Surface-Modified GBM Targeted Nanoparticles: Targeting Strategies and Surface Characterization. Int J Mol Sci. 2023 Jan 27;24(3):2496. doi: 10.3390/ijms24032496.
  79. Toljan K, Ashok A, Labhasetwar V, Hussain MS. Nanotechnology in Stroke: New Trails with Smaller Scales. Biomedicines. 2023 Mar 4;11(3):780. doi: 10.3390/biomedicines11030780.
  80. Kindy MS, Vertegel A. Nanoparticles for Neurotherapeutic Drug Delivery in Neurodegenerative Disorders: Application in Neurotrauma. In: Kobeissy FH, editor. Brain Neurotrauma: Molecular, Neuropsychological, and Rehabilitation Aspects. Boca Raton (FL): CRC Press/Taylor & Francis; 2015. Chapter 41. Available from: https://www.ncbi.nlm.nih.gov/books/NBK299207/
  81. Chountoulesi M, Demetzos C. Promising Nanotechnology Approaches in Treatment of Autoimmune Diseases of Central Nervous System. Brain Sci. 2020 Jun 2;10(6):338. doi: 10.3390/brainsci10060338.
  82. Mitarotonda R, Giorgi E, Eufrasio-da-Silva T, Dolatshahi-Pirouz A, Mishra YK, Khademhosseini A, et al. Immunotherapeutic nanoparticles: From autoimmune disease control to the development of vaccines. Biomater Adv. 2022 Apr;135:212726. doi: 10.1016/j.bioadv.2022.212726.
  83. Monge-Fuentes V, Biolchi Mayer A, Lima MR, Geraldes LR, Zanotto LN, Moreira KG, et al. Dopamine-loaded nanoparticle systems circumvent the blood-brain barrier restoring motor function in mouse model for Parkinson's Disease. Sci Rep. 2021 Jul 26;11(1):15185. doi: 10.1038/s41598-021-94175-8.
  84. Alabrahim OAA, Azzazy HME. Polymeric nanoparticles for dopamine and levodopa replacement in Parkinson's disease. Nanoscale Adv. 2022 Nov 3;4(24):5233-5244. doi: 10.1039/d2na00524g.
  85. Xu Y, Dong X, Xu H, Jiao P, Zhao LX, Su G. Nanomaterial-Based Drug Delivery Systems for Pain Treatment and Relief: From the Delivery of a Single Drug to Co-Delivery of Multiple Therapeutics. Pharmaceutics. 2023 Sep 13;15(9):2309. doi: 10.3390/pharmaceutics15092309.
  86. Szok D, Tajti J, Nyári A, Vécsei L. Therapeutic Approaches for Peripheral and Central Neuropathic Pain. Behav Neurol. 2019 Nov 21;2019:8685954. doi: 10.1155/2019/8685954.
  87. Kim CG, Lee JC, Ju DB, Kim SK, Yun CH, Cho CS. Enhancement of Immune Responses Elicited by Nanovaccines through a Cross-Presentation Pathway. Tissue Eng Regen Med. 2023 Jun;20(3):355-370. doi: 10.1007/s13770-023-00527-y.
  88. Azharuddin M, Zhu GH, Sengupta A, Hinkula J, Slater NKH, Patra HK. Nano toolbox in immune modulation and nanovaccines. Trends Biotechnol. 2022 Oct;40(10):1195-1212. doi: 10.1016/j.tibtech.2022.03.011.
  89. Bezbaruah R, Chavda VP, Nongrang L, Alom S, Deka K, Kalita T, Ali F, Bhattacharjee B, Vora L. Nanoparticle-Based Delivery Systems for Vaccines. Vaccines (Basel). 2022 Nov 17;10(11):1946. doi: 10.3390/vaccines10111946.
  90. Xie J, Shen Z, Anraku Y, Kataoka K, Chen X. Nanomaterial-based blood-brain-barrier (BBB) crossing strategies. Biomaterials. 2019 Dec;224:119491. doi: 10.1016/j.biomaterials.2019.119491.
  91. Mangla B, Javed S, Sultan MH, Ahsan W, Aggarwal G, Kohli K. Nanocarriers-Assisted Needle-Free Vaccine Delivery Through Oral and Intranasal Transmucosal Routes: A Novel Therapeutic Conduit. Front Pharmacol. 2022 Jan 11;12:757761. doi: 10.3389/fphar.2021.757761.
  92. Du G, Qin M, Sun X. Recent progress in application of nanovaccines for enhancing mucosal immune responses. Acta Pharm Sin B. 2023 Jun;13(6):2334-2345. doi: 10.1016/j.apsb.2022.08.010.
  93. Tang W, Zhang Y, Zhu G. Pulmonary delivery of mucosal nanovaccines. Nanoscale. 2022 Jan 6;14(2):263-276. doi: 10.1039/d1nr06512b.
  94. Dotiwala F, Upadhyay AK. Next Generation Mucosal Vaccine Strategy for Respiratory Pathogens. Vaccines (Basel). 2023 Oct 12;11(10):1585. doi: 10.3390/vaccines11101585.
  95. Bhardwaj P, Bhatia E, Sharma S, Ahamad N, Banerjee R. Advancements in prophylactic and therapeutic nanovaccines. Acta Biomater. 2020 May;108:1-21. doi: 10.1016/j.actbio.2020.03.020.
  96. Huang Y, Guo X, Wu Y, Chen X, Feng L, Xie N, Shen G. Nanotechnology's frontier in combatting infectious and inflammatory diseases: prevention and treatment. Signal Transduct Target Ther. 2024 Feb 21;9(1):34. doi: 10.1038/s41392-024-01745-z.
  97. Yao M, Liu X, Qian Z, Fan D, Sun X, Zhong L, Wu P. Research progress of nanovaccine in anti-tumor immunotherapy. Front Oncol. 2023 Aug 24;13:1211262. doi: 10.3389/fonc.2023.1211262.
  98. Tang Y, Li L. The Application of Nanovaccines in Autoimmune Diseases. Int J Nanomedicine. 2024 Jan 12;19:367-388. doi: 10.2147/IJN.S440612.
  99. Li H, Yang YG, Sun T. Nanoparticle-Based Drug Delivery Systems for Induction of Tolerance and Treatment of Autoimmune Diseases. Front Bioeng Biotechnol. 2022 Apr 6;10:889291. doi: 10.3389/fbioe.2022.889291.
  100. Huang M, Zhang M, Zhu H, Du X, Wang J. Mucosal vaccine delivery: A focus on the breakthrough of specific barriers. Acta Pharm Sin B. 2022 Sep;12(9):3456-3474. doi: 10.1016/j.apsb.2022.07.002.
  101. Soto F, Wang J, Ahmed R, Demirci U. Medical Micro/Nanorobots in Precision Medicine. Adv Sci (Weinh). 2020 Oct 4;7(21):2002203. doi: 10.1002/advs.202002203.
  102. Roy A, Sharma A, Yadav S, Jule LT, Krishnaraj R. Nanomaterials for Remediation of Environmental Pollutants. Bioinorg Chem Appl. 2021 Dec 28;2021:1764647. doi: 10.1155/2021/1764647.

JCMCRI
ISSN: 3064-8025

Journal of Clinical & Medical Case Reports, Images (JCMCRI) ISSN: 3064-8025 is a peer-reviewed journal dedicated to publishing clinical images from all sectors of medicine. The goal of this magazine is to disseminate information about new discoveries and treatments in science and medicine.

Quick Links

OTHER LINKS

Contact Us

Journal of Clinical & Medical Case Reports, Images , Frisco, Texas 75070, USA

support@jcmcrimages.org

+1 (231) 999-1496

Copyright ©2024 All rights reserved

TOP